Plain-English translation of NCT06930755 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new drug called combined with an existing chemotherapy drug called in people whose ovarian cancer has returned after previous treatments. Researchers want to find the right dose of this medication, understand how safe it is, and see whether it helps shrink tumors. The study will include about 24 patients.
Ovarian cancer that comes back after initial treatment is very difficult to manage, and patients need new treatment options. This medication belongs to a newer class of drugs designed to work differently than standard treatments, and this study will test whether combining it with chemotherapy is a promising approach for patients who have limited options left.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth twice daily for 7 days out of every 4-week cycle, and receive the chemotherapy drug through an IV infusion once a week for three weeks of each cycle. You would have regular visits with the research team to check how you are tolerating the treatment, have blood tests and scans to see if your cancer is responding, and complete follow-up visits to monitor your health. The study involves about 24 patients at multiple medical centers.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States